Dr. William Brose, director of the Pain Management Center for Stanford University, reported detailed study results from a chronic pain study with SNX-111 at the American Pain Society on November 16, 1996.
The paper, entitled, "Analgesia Produced by SNX-111 in Patients With Morphine(Drug information on morphine)-Resistant Pain," represented the work from multiple centers and described both the safety and efficacy of SNX-111 in this study to treat patients with very severe pain. SNX-111 is the lead pain therapeutic under development by Neurex Corporation.
The majority of patients who were considered evaluable in this study showed a measurable reduction in pain scores, as judged by both patient and physician. In addition, most patients also had a significant reduction in other medications that had been used prior to the study in an attempt to treat, albeit unsuccessfully, their pain symptoms.
Over two-thirds of the 24 patients had a 50% or greater reduction in medication, with some patients totally eliminating morphine/narcotic use.
"Although the study was primarily designed to evaluate the feasibility and efficacy of SNX-111 treatment in these severely ill patients, it is clear that as a patient group, a majority of these individuals seem to have benefited from improvements in their pain symptoms with SNX-111 treatment," commented Dr. Brose.
"To see such a reduction in both their pain scores and use of their pain medications in this patient population is quite remarkable. For patients with prolonged and unremitting pain, SNX-111 represents potential hope and light at the end of a very long and dark tunnel."
The study evaluated the safety and efficacy of intraspinally administered SNX-111 in patients who had previously failed morphine therapy. Study guidelines required that patients had to have failed all other pain treatment (including intraspinal morphine and other narcotics) prior to study enrollment.
Patients entered into the study had various types of severe and resistant pain, including those who were suffering from cancer, AIDS, neuropathies, spinal cord injuries, and phantom limb pain.